Evidence map›Paper›PMID 23770856›Full record

ArticleOncogene2014

Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.

C C Jiang, A Croft, H-Y Tseng, S T Guo, L Jin, P Hersey, X D Zhang

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2021
    Review
  6. Article
  7. Article
  8. The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma.International journal of molecular sciences · 2020
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

C C Jiang1] Priority Research Centre for Cancer Research, University of Newcastle, Callaghan, NSW, Australia [2] School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
A Croft1] Priority Research Centre for Cancer Research, University of Newcastle, Callaghan, NSW, Australia [2] Oncology and Immunology Unit, Calvary Mater Newcastle Hospital, Waratah, NSW, Australia.
H-Y Tseng1] Priority Research Centre for Cancer Research, University of Newcastle, Callaghan, NSW, Australia [2] School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia.
S T GuoDepartment of Molecular Biology, Shanxi Cancer Hospital and Institute, Taiyuan, Shanxi, People's Republic of China.
L JinKolling Institute for Medical Research, University of Sydney, St Leonards, NSW, Australia.
P HerseyKolling Institute for Medical Research, University of Sydney, St Leonards, NSW, Australia.
X D Zhang1] Priority Research Centre for Cancer Research, University of Newcastle, Callaghan, NSW, Australia [2] School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia [3] Department of Molecular Biology, Shanxi Cancer Hospital and Institute, Taiyuan, Shanxi, People's Republic of China.
University of Sydney · AUShanxi Provincial Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increased global protein synthesis and selective translation of mRNAs encoding proteins contributing to malignancy is common in cancer cells. This is often associated with elevated expression of eukaryotic translation initiation factor 4 (eIF4E), the rate-limiting factor of cap-dependent translation initiation. We report here that in human melanoma downregulation of miR-768-3p as a result of activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway has an important role in the upregulation of eIF4E and enhancement in protein synthesis. Melanoma cells displayed increased nascent protein production and elevated eIF4E expression, which was associated with the downregulation of miR-768-3p that was predicted to target the 3'-untranslated region of the eIF4E mRNA. Overexpression of miR-768-3p led to the downregulation of the endogenous eIF4E protein, reduction in nascent protein synthesis and inhibition of cell survival and proliferation. These effects were efficiently reversed when eIF4E was co-overexpressed in melanoma cells. On the other hand, introduction of anti-miR-768-3p into melanocytes upregulated endogenous eIF4E protein expression and increased global protein synthesis. Downregulation of miR-768-3p appeared to be mediated by activation of the MEK/ERK pathway, in that treatment of BRAF(V600E) melanoma cells with the mutant BRAF inhibitor PLX4720 or exposure of either BRAF(V600E) or wild-type BRAF melanoma cells to the MEK inhibitor U0126 resulted in the upregulation of miR-768-3p and inhibition of nascent protein synthesis. This inhibition was partially blocked in cells cointroduced with anti-miR-768-3p. Significantly, miR-768-3p was similarly downregulated, which was inversely associated with the expression levels of eIF4E in fresh melanoma isolates. Taken together, these results identify downregulation of miR-768-3p and subsequent upregulation of eIF4E as an important mechanism in addition to phosphorylation of eIF4E responsible for MEK/ERK-mediated enhancement of protein synthesis in melanoma.

Indexed as

MAP Kinase Signaling SystemProtein BiosynthesisSignal TransductionCell Line, TumorDown-RegulationEukaryotic Initiation Factor-4EHumansMelanomaMicroRNAsRNA, MessengerUp-RegulationEukaryotic Initiation Factor-4EMicroRNAsMIRN768 microRNA, humanRNA, Messenger

Identifiers

PMID23770856
OpenAlexW2027814240

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.